Based on the Alnylam Pharmaceuticals Inc stock forecasts from 11 analysts, the average analyst target price for Alnylam Pharmaceuticals Inc is USD 224.56 over the next 12 months. Alnylam Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Alnylam Pharmaceuticals Inc is Neutral, which is based on 3 positive signals and 3 negative signals. At the last closing, Alnylam Pharmaceuticals Inc’s stock price was USD 134.01. Alnylam Pharmaceuticals Inc’s stock price has changed by +8.21% over the past week, -0.74% over the past month and -11.30% over the last year.
This week, STA Research assigned the stock with a Buy rating and a $155 target on the stock.
William Blair also initiated coverage of the stock with a Outperform rating.
The biopharmaceutical company Alnylam Pharmaceuticals, Inc. focuses on the research, development, and commercialization of novel therapeutics that are based on ribonucleic acid interference.
The year 2002 marked the beginning of operations for the company, which now has its headquarters in Cambridge, Massachusetts. Cambridge, Massachusetts, United States, 02142, Street Address: 675 West Kendall Street
What we like:
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What we don’t like:
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The company had negative total cash flow in the most recent four quarters.